Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Onkologia w Praktyce Klinicznej - Edukacja
MENU
Na skróty Ahead of print Zdeponuj artykuł Nagroda imienia Profesora Krzysztofa Krzemienieckiego Zalecenia postępowania diagnostyczno-terapeutycznego

dostęp otwarty

Tom 8, Nr 6 (2022)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2022-05-27
Pokaż PDF Pokaż HTML
Pobierz cytowanie

Zalecenia postępowania diagnostyczno-terapeutycznego w raku nerkowokomórkowym — aktualizacja

Piotr J. Wysocki1, Piotr Chłosta2, Robert Chrzan3, Anna K. Czech2, Katarzyna Gronostaj2, Kamil Konopka1, Maciej Krzakowski4, Jakub Kucharz5, Krzysztof Małecki6, Mikołaj Przydacz2, Piotr Tomczak7, Paweł Wiechno5, Jakub Żołnierek5
Onkol Prakt Klin Edu 2022;8(6):424-457.
Afiliacje
  1. Katedra i Klinika Onkologii, Uniwersytet Jagielloński — Collegium Medicum w Krakowie
  2. Katedra i Klinika Urologii, Uniwersytet Jagielloński — Collegium Medicum w Krakowie
  3. Katedra Radiologii, Uniwersytet Jagielloński — Collegium Medicum w Krakowie
  4. Klinika Nowotworów Płuca i Klatki Piersiowej, Narodowy Instytut Onkologii im. M. Skłodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie
  5. Klinika Nowotworów Układu Moczowego, Narodowy Instytut Onkologii im. M. Skłodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie
  6. Zakład Radioterapii Dzieci i Dorosłych, Uniwersytecki Szpital Dziecięcy w Krakowie
  7. Klinika Onkologii, Uniwersytet Medyczny w Poznaniu

dostęp otwarty

Tom 8, Nr 6 (2022)
WYTYCZNE POSTĘPOWANIA DIAGNOSTYCZNO-TERAPEUTYCZNEGO
Opublikowany online: 2022-05-27

Streszczenie

Brak

Streszczenie

Brak

Pełny tekst:

Pokaż PDF Pokaż HTML
Pobierz cytowanie

Słowa kluczowe

rak nerkowokomórkowy; nefrektomia; leczenie celowane; inhibitory kinaz tyrozynowych; immunoterapia; terapia antyangiogenna; rak nerki; diagnostyka; leczenie

Informacje o artykule
Tytuł

Zalecenia postępowania diagnostyczno-terapeutycznego w raku nerkowokomórkowym — aktualizacja

Czasopismo

Onkologia w Praktyce Klinicznej - Edukacja

Numer

Tom 8, Nr 6 (2022)

Typ artykułu

Wytyczne / stanowisko ekspertów

Strony

424-457

Opublikowany online

2022-05-27

Wyświetlenia strony

1465

Wyświetlenia/pobrania artykułu

931

Rekord bibliograficzny

Onkol Prakt Klin Edu 2022;8(6):424-457.

Słowa kluczowe

rak nerkowokomórkowy
nefrektomia
leczenie celowane
inhibitory kinaz tyrozynowych
immunoterapia
terapia antyangiogenna
rak nerki
diagnostyka
leczenie

Autorzy

Piotr J. Wysocki
Piotr Chłosta
Robert Chrzan
Anna K. Czech
Katarzyna Gronostaj
Kamil Konopka
Maciej Krzakowski
Jakub Kucharz
Krzysztof Małecki
Mikołaj Przydacz
Piotr Tomczak
Paweł Wiechno
Jakub Żołnierek

Referencje (182)
  1. Montori VM, Guyatt GH. Progress in evidence-based medicine. JAMA. 2008; 300(15): 1814–1816.
    CrossRefPubMed
  2. Kiesewetter B, Cherny NI, Boissel N, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017; 28(10): 2340–2366.
    CrossRefPubMed
  3. Krzakowski M, Wysocki P, Jassem J, et al. Algorytm oceny wartości nowych leków przeciwnowotworowych — propozycje Polskiego Towarzystwa Onkologii Klinicznej i Polskiego Towarzystwa Onkolo- gicznego. Onkol Prak Klin. 2015; 11(1): 9–15.
  4. Antwi SO, Eckel-Passow JE, Diehl ND, et al. Coffee consumption and risk of renal cell carcinoma. Cancer Causes Control. 2017; 28(8): 857–866.
    CrossRefPubMed
  5. Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology. 2005; 236(2): 441–450.
    CrossRefPubMed
  6. Choudhary S, Rajesh A, Mayer NJ, et al. Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms. Clin Radiol. 2009; 64(5): 517–522.
    CrossRefPubMed
  7. Hindman N, Ngo L, Genega EM, et al. Angiomyolipoma with minimal fat: can it be differentiated from clear cell renal cell carcinoma by using standard MR techniques? Radiology. 2012; 265(2): 468–477.
    CrossRefPubMed
  8. Silverman SG, Pedrosa I, Ellis JH, et al. Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment. Radiology. 2019; 292(2): 475–488.
    CrossRefPubMed
  9. Kang SK, Zhang A, Pandharipande PV, et al. DWI for Renal Mass Characterization: Systematic Review and Meta-Analysis of Diagnostic Test Performance. AJR Am J Roentgenol. 2015; 205(2): 317–324.
    CrossRefPubMed
  10. Mueller-Lisse UG, Mueller-Lisse UL. Imaging of advanced renal cell carcinoma. World J Urol. 2010; 28(3): 253–261.
    CrossRefPubMed
  11. Putra LG, Minor TX, Bolton DM, et al. Improved assessment of renal lesions in pregnancy with magnetic resonance imaging. Urology. 2009; 74(3): 535–539.
    CrossRefPubMed
  12. Defortescu G, Cornu JN, Béjar S, et al. Diagnostic performance of contrast-enhanced ultrasonography and magnetic resonance imaging for the assessment of complex renal cysts: A prospective study. Int J Urol. 2017; 24(3): 184–189.
    CrossRefPubMed
  13. Capogrosso P, Capitanio U, La Croce G, et al. Follow-up After Treatment for Renal Cell Carcinoma: The Evidence Beyond the Guidelines. Eur Urol Focus. 2016; 1(3): 272–281.
    CrossRefPubMed
  14. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007; 243(1): 148–157.
    CrossRefPubMed
  15. Grünwald V, Eberhardt B, Bex A, et al. An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nat Rev Urol. 2018; 15(8): 511–521.
    CrossRefPubMed
  16. Liu Y. The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations. Front Oncol. 2016; 6: 201.
    CrossRefPubMed
  17. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17(6): 1471–1474.
    CrossRefPubMed
  18. Verhoest G, Avakian R, Bensalah K, et al. Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol. 2009; 182(3): 854–859.
    CrossRefPubMed
  19. Anderson CB, Clark PE, Morgan TM, et al. Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. Urology. 2011; 78(1): 99–104.
    CrossRefPubMed
  20. Gilbert SM, Murphy AM, Katz AE, et al. Reevaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. Urology. 2006; 68(2): 287–291.
    CrossRefPubMed
  21. Alt AL, Boorjian SA, Lohse CM, et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011; 117(13): 2873–2882.
    CrossRefPubMed
  22. Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000; 163(4): 1090–5; quiz 1295.
    CrossRefPubMed
  23. Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005; 104(3): 511–520.
    CrossRefPubMed
  24. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20(1): 289–296.
    CrossRefPubMed
  25. Heng DYC, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013; 14(2): 141–148.
    CrossRefPubMed
  26. Ko JJ, Xie W, Kroeger N, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015; 16(3): 293–300.
    CrossRefPubMed
  27. Hollingsworth JM, Miller DC, Daignault S, et al. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007; 109(9): 1763–1768.
    CrossRefPubMed
  28. Lane BR, Abouassaly R, Gao T, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer. 2010; 116(13): 3119–3126.
    CrossRefPubMed
  29. Smaldone MC, Kutikov A, Egleston BL, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer. 2012; 118(4): 997–1006.
    CrossRefPubMed
  30. Pierorazio PM, Johnson MH, Ball MW, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol. 2015; 68(3): 408–415.
    CrossRefPubMed
  31. Uzosike AC, Patel HD, Alam R, et al. Growth kinetics of small renal masses on active surveillance: variability and results from the DISSRM registry. J Urol. 2018; 199(3): 641–648.
    CrossRefPubMed
  32. Jiang K, Tang K, Guo X, et al. Laparoscopic cryoablation vs. percutaneous cryoablation for treatment of small renal masses: a systematic review and meta-analysis. Oncotarget. 2017; 8(16): 27635–27644.
    CrossRefPubMed
  33. Aboumarzouk OM, Ismail M, Breen DJ, et al. Laparoscopic vs Percutaneous Cryotherapy for Renal Tumors: A Systematic Review and Meta-Analysis. J Endourol. 2018; 32(3): 177–183.
    CrossRefPubMed
  34. O'Malley RL, Berger AD, Kanofsky JA, et al. A matched-cohort comparison of laparoscopic cryoablation and laparoscopic partial nephrectomy for treating renal masses. BJU Int. 2007; 99(2): 395–398.
    CrossRefPubMed
  35. Ko YH, Park HS, Moon DuG, et al. A matched-cohort comparison of laparoscopic renal cryoablation using ultra-thin cryoprobes with open partial nephrectomy for the treatment of small renal cell carcinoma. Cancer Res Treat. 2008; 40(4): 184–189.
    CrossRefPubMed
  36. Guillotreau J, Haber GP, Autorino R, et al. Robotic partial nephrectomy versus laparoscopic cryoablation for the small renal mass. Eur Urol. 2012; 61(5): 899–904.
    CrossRefPubMed
  37. Deng W, Chen L, Wang Y, et al. Cryoablation versus Partial Nephrectomy for Clinical Stage T1 Renal Masses: A Systematic Review and Meta-Analysis. J Cancer. 2019; 10(5): 1226–1236.
    CrossRefPubMed
  38. Trudeau V, Larcher A, Boehm K, et al. Comparison of Postoperative Complications and Mortality Between Laparoscopic and Percutaneous Local Tumor Ablation for T1a Renal Cell Carcinoma: A Population-based Study. Urology. 2016; 89: 63–67.
    CrossRefPubMed
  39. Young EE, Castle SM, Gorbatiy V, et al. Comparison of safety, renal function outcomes and efficacy of laparoscopic and percutaneous radio frequency ablation of renal masses. J Urol. 2012; 187(4): 1177–1182.
    CrossRefPubMed
  40. Lian H, Guo H, Zhang G, et al. Single-center comparison of complications in laparoscopic and percutaneous radiofrequency ablation with ultrasound guidance for renal tumors. Urology. 2012; 80(1): 119–124.
    CrossRefPubMed
  41. Kim SD, Yoon SG, Sung GT. Radiofrequency ablation of renal tumors: four-year follow-up results in 47 patients. Korean J Radiol. 2012; 13(5): 625–633.
    CrossRefPubMed
  42. Patel N, Cranston D, Akhtar MZ, et al. Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU Int. 2012; 110(9): 1270–1275.
    CrossRefPubMed
  43. Takaki H, Yamakado K, Soga N, et al. Midterm results of radiofrequency ablation versus nephrectomy for T1a renal cell carcinoma. Jpn J Radiol. 2010; 28(6): 460–468.
    CrossRefPubMed
  44. Pan XW, Cui XM, Huang H, et al. Radiofrequency ablation versus partial nephrectomy for treatment of renal masses: A systematic review and meta-analysis. Kaohsiung J Med Sci. 2015; 31(12): 649–658.
    CrossRefPubMed
  45. Rivero JR, De La Cerda J, Wang H, et al. Partial Nephrectomy versus Thermal Ablation for Clinical Stage T1 Renal Masses: Systematic Review and Meta-Analysis of More than 3,900 Patients. J Vasc Interv Radiol. 2018; 29(1): 18–29.
    CrossRefPubMed
  46. Atwell TD, Schmit GD, Boorjian SA, et al. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am J Roentgenol. 2013; 200(2): 461–466.
    CrossRefPubMed
  47. Samarasekera D, Khalifeh A, Autorino R, et al. 1795 percutaneous radiofrequency ablation versus percutaneous cryoablation: long-term outcomes following ablation for renal cell carcinoma. Journal of Urology. 2013; 189(4S).
    CrossRef
  48. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011; 59(4): 543–552.
    CrossRefPubMed
  49. Butler BP, Novick AC, Miller DP, et al. Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. Urology. 1995; 45(1): 34–40; discussion 40.
    CrossRefPubMed
  50. D’Armiento M, Damiano R, Feleppa B, et al. Elective conservative surgery for renal carcinoma versus radical nephrectomy: a pro- spective study. Br J Urol. 1997; 79(1): 15–19.
    CrossRefPubMed
  51. Gratzke C, Seitz M, Bayrle F, et al. Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma. BJU Int. 2009; 104(4): 470–475.
    CrossRefPubMed
  52. Kunath F, Schmidt S, Krabbe LM, et al. Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. Cochrane Database Syst Rev. 2017; 5: CD012045.
    CrossRefPubMed
  53. Sun M, Bianchi M, Trinh QD, et al. Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities. BJU Int. 2013; 111(1): 67–73.
    CrossRefPubMed
  54. Shuch B, Hanley J, Lai J, et al. Urologic Diseases in America Project. Overall survival advantage with partial nephrectomy: a bias of ob- servational data? Cancer. 2013; 119(16): 2981–2989.
    CrossRefPubMed
  55. MacLennan S, Imamura M, Lapitan MC, et al. Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. Eur Urol. 2012; 62(6): 1097–1117.
    CrossRefPubMed
  56. Shekarriz B, Upadhyay J, Shekarriz H, et al. Comparison of costs and complications of radical and partial nephrectomy for treatment of localized renal cell carcinoma. Urology. 2002; 59(2): 211–215.
    CrossRefPubMed
  57. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2007; 51(6): 1606–1615.
    CrossRefPubMed
  58. Miller D, Schonlau M, Litwin M, et al. Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer. 2008; 112(3): 511–520.
    CrossRef
  59. Mir MC, Derweesh I, Porpiglia F, et al. Partial nephrectomy versus rad- ical nephrectomy for clinical T1B and T2 renal mass: A meta-analysis of over 9000 cases. J Urol. 2016.
  60. Janssen M, Linxweiler J, Terwey S, et al. Survival outcomes in patients with large (≥7cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: Results of a multicenter cohort with long-term follow-up. PLOS ONE. 2018; 13(5): e0196427.
    CrossRef
  61. Hemal AK, Kumar A, Kumar R, et al. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. J Urol. 2007; 177(3): 862–866.
    CrossRefPubMed
  62. Laparoscopic radical nephrectomy and laparoscopic partial nephrectomy for renal cell carcinoma. Clinical Progress in Renal Cancer. 2007: 129–140.
    CrossRef
  63. Nadler RB, Loeb S, Clemens JQ, et al. A prospective study of laparoscopic radical nephrectomy for T1 tumors--is transperitoneal, retroperitoneal or hand assisted the best approach? J Urol. 2006; 175(4): 1230–3; discussion 1234.
    CrossRefPubMed
  64. Desai MM, Strzempkowski B, Matin SF, et al. Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy. J Urol. 2005; 173(1): 38–41.
    CrossRefPubMed
  65. Asimakopoulos AD, Miano R, Annino F, et al. Robotic radical nephrectomy for renal cell carcinoma: a systematic review. BMC Urol. 2014; 14: 75.
    CrossRefPubMed
  66. Lane BR, Gill IS. 7-year oncological outcomes after laparoscopic and open partial nephrectomy. J Urol. 2010; 183(2): 473–479.
    CrossRefPubMed
  67. Gill IS, Kavoussi LR, Lane BR, et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol. 2007; 178(1): 41–46.
    CrossRefPubMed
  68. Gong EM, Orvieto MA, Zorn KC, et al. Comparison of laparoscopic and open partial nephrectomy in clinical T1a renal tumors. J Endourol. 2008; 22(5): 953–957.
    CrossRefPubMed
  69. Minervini A, Ficarra V, Rocco F, et al. Simple enucleation is equivalent to traditional partial nephrectomy for renal cell carcinoma: results of a nonrandomized, retrospective, comparative study. J Urol. 2011; 185(5): 1604–1610.
    CrossRefPubMed
  70. Chang KiD, Abdel Raheem A, Kim KH, et al. Functional and oncological outcomes of open, laparoscopic and robot-assisted partial nephrectomy: a multicentre comparative matched-pair analyses with a median of 5 years' follow-up. BJU Int. 2018; 122(4): 618–626.
    CrossRefPubMed
  71. Masson-Lecomte A, Yates DR, Hupertan V, et al. A prospective comparison of the pathologic and surgical outcomes obtained after elective treatment of renal cell carcinoma by open or robot-assisted partial nephrectomy. Urol Oncol. 2013; 31(6): 924–929.
    CrossRefPubMed
  72. Peyronnet B, Seisen T, Oger E, et al. Comparison of 1800 Robotic and Open Partial Nephrectomies for Renal Tumors . Ann Surg Oncol. 2016; 23(13): 4277–4283.
    CrossRefPubMed
  73. Choi JiE, You JiH, Kim DK, et al. Comparison of perioperative outcomes between robotic and laparoscopic partial nephrectomy: a systematic review and meta-analysis. Eur Urol. 2015; 67(5): 891–901.
    CrossRefPubMed
  74. Arora S, Keeley J, Pucheril D, et al. What is the hospital volume threshold to optimize inpatient complication rate after partial nephrectomy? Urol Oncol. 2018; 36(7): 339.e17–339.e23.
    CrossRefPubMed
  75. Peyronnet B, Tondut L, Bernhard JC, et al. Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy outcomes: a multicentre study. BJU Int. 2018; 121(6): 916–922.
    CrossRefPubMed
  76. Wood EL, Adibi M, Qiao W, et al. Local tumor bed recurrence following partial nephrectomy in patients with small renal masses. J Urol. 2018; 199(2): 393–400.
    CrossRefPubMed
  77. Bensalah K, Pantuck AJ, Rioux-Leclercq N, et al. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol. 2010; 57(3): 466–471.
    CrossRefPubMed
  78. Tabayoyong W, Abouassaly R, Kiechle JE, et al. Variation in Surgical Margin Status by Surgical Approach among Patients Undergoing Partial Nephrectomy for Small Renal Masses. J Urol. 2015; 194(6): 1548–1553.
    CrossRefPubMed
  79. Kim SP, Abouassaly R. Treatment of patients with positive margins after partial nephrectomy. J Urol. 2016; 196(2): 301–302.
    CrossRefPubMed
  80. Blom JHM, van Poppel H, Maréchal JM, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 2009; 55(1): 28–34.
    CrossRefPubMed
  81. Bacic J, Liu T, Thompson RH, et al. Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis. Eur Urol. 2017; 71(4): 560–567.
    CrossRefPubMed
  82. Whitson JM, Harris CR, Reese AC, et al. Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. J Urol. 2011; 185(5): 1615–1620.
    CrossRefPubMed
  83. Capitanio U, Suardi N, Matloob R, et al. Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). BJU Int. 2014; 114(2): 210–215.
    CrossRefPubMed
  84. Lane BR, Tiong HY, Campbell SC, et al. Management of the adrenal gland during partial nephrectomy. J Urol. 2009; 181(6): 2430–6; discussion 2436.
    CrossRefPubMed
  85. May M, Brookman-Amissah S, Pflanz S, et al. Pre-operative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma. Br J Radiol. 2009; 82(981): 724–731.
    CrossRefPubMed
  86. Subramanian VS, Stephenson AJ, Goldfarb DA, et al. Utility of preoperative renal artery embolization for management of renal tumors with inferior vena caval thrombi. Urology. 2009; 74(1): 154–159.
    CrossRefPubMed
  87. Lamb GWA, Bromwich EJ, Vasey P, et al. Management of renal masses in patients medically unsuitable for nephrectomy--natural history, complications, and outcome. Urology. 2004; 64(5): 909–913.
    CrossRefPubMed
  88. Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol. 2004; 171(2 Pt 1): 598–601.
    CrossRefPubMed
  89. Pritchett TR, Lieskovsky G, Skinner DG. Extension of renal cell carcinoma into the vena cava: clinical review and surgical approach. J Urol. 1986; 135(3): 460–464.
    CrossRefPubMed
  90. Wilkinson CJ, Kimovec MA, Uejima T. Cardiopulmonary bypass in patients with malignant renal neoplasms. Br J Anaesth. 1986; 58(4): 461–465.
    CrossRefPubMed
  91. Libertino JA, Zinman L, Watkins E. Long-term results of resection of renal cell cancer with extension into inferior vena cava. J Urol. 1987; 137(1): 21–24.
    CrossRefPubMed
  92. Neves RJ, Zincke H. Surgical treatment of renal cancer with vena cava extension. Br J Urol. 1987; 59(5): 390–395.
    CrossRefPubMed
  93. Novick A, Streem S, Pontes E. Stewart’s Operative Urology. 2nd ed. Philadelphia: Williams & Wilkins. 1989.
  94. Hinman F. Atlas of Urologic Surgery. 2nd ed. Philadelphia: WB Saunders Co. 1998.
  95. Nesbitt JC, Soltero ER, Dinney CP, et al. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Ann Thorac Surg. 1997; 63(6): 1592–1600.
    CrossRefPubMed
  96. Hatcher PA, Anderson EE, Paulson DF, et al. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol. 1991; 145(1): 20–3; discussion 23.
    CrossRefPubMed
  97. Orihashi K, Sueda T, Usui T, et al. Deep hypothermic circulatory arrest for resection of renal tumor in the inferior vena cava: beneficial or deleterious? Circ J. 2008; 72(7): 1175–1177.
    CrossRefPubMed
  98. Martínez-Salamanca JI, Huang WC, Millán I, et al. Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol. 2011; 59(1): 120–127.
    CrossRefPubMed
  99. Klaver S, Joniau S, Suy R, et al. Analysis of renal cell carcinoma with subdiaphragmatic macroscopic venous invasion (T3b). BJU International. 2007; 0(0).
    CrossRef
  100. Ficarra V, Galfano A, Guillé F, et al. A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients. J Urol. 2007; 178(2): 418–24; discussion 423.
    CrossRefPubMed
  101. Motzer RJ, Haas NB, Donskov F, et al. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. J Clin Oncol. 2017; 35(35): 3916–3923.
    CrossRefPubMed
  102. Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016; 387(10032): 2008–2016.
    CrossRefPubMed
  103. Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med. 2016; 375(23): 2246–2254.
    CrossRefPubMed
  104. Choueiri TK, Tomczak P, Park SeH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021; 385(8): 683–694.
    CrossRefPubMed
  105. Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016; 17(9): 1317–1324.
    CrossRefPubMed
  106. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004; 171(3): 1071–1076.
    CrossRefPubMed
  107. Hanna N, Sun M, Meyer CP, et al. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. J Clin Oncol. 2016; 34(27): 3267–3275.
    CrossRefPubMed
  108. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018; 379(5): 417–427.
    CrossRefPubMed
  109. Bex A, Mulders P, Jewett M, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 2019; 5(2): 164–170.
    CrossRefPubMed
  110. Mejean A, Thezenas S, Chevreau C, et al. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population. J Clin Oncol. 2019; 37(15_suppl): 4508–4508.
    CrossRef
  111. Freed SZ, Halperin JP, Gordon M. Idiopathic regression of metastases from renal cell carcinoma. J Urol. 1977; 118(4): 538–542.
    CrossRefPubMed
  112. Marcus SG, Choyke PL, Reiter R, et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol. 1993; 150(2 Pt 1): 463–466.
    CrossRefPubMed
  113. Barney J, Churchill E. Adenocarcinoma of the Kidney with Metastasis to the Lung: Cured by Nephrectomy and Lobectomy. J Urol. 1939; 42(3): 269–276.
    CrossRef
  114. Ouzaid I, Capitanio U, Staehler M, et al. Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. Eur Urol Oncol. 2019; 2(2): 141–149.
    CrossRefPubMed
  115. Achkar T, Maranchie J, Appleman L. Metastasectomy in Advanced Renal Cell Carcinoma: A Systematic Review. Kidney Cancer. 2019; 3(1): 31–40.
    CrossRef
  116. Larkin J, Eisen T. Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2006; 60(3): 216–226.
    CrossRef
  117. Gordon MS. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. Yearbook of Oncology. 2010; 2010: 103–104.
    CrossRef
  118. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369(8): 722–731.
    CrossRefPubMed
  119. Escudier B, Porta C, Bono P. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazo- panib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 2014; 32(14): 1412–1418.
    CrossRefPubMed
  120. Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013; 31(30): 3791–3799.
    CrossRefPubMed
  121. Nosov DA, Esteves B, Lipatov ON, et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol. 2012; 30(14): 1678–1685.
    CrossRefPubMed
  122. Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013; 14(13): 1287–1294.
    CrossRefPubMed
  123. Choueiri T, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018; 94: 115–125.
    CrossRefPubMed
  124. Brown JE, Royle KL, Ralph C, et al. LBA28 STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC). Annals of Oncology. 2021; 32: S1303–S1304.
    CrossRef
  125. Hudes GR, Carducci MA, Choueiri TK, et al. lobal ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Eng J Med. 2007; 356(22): 2271–2281.
    CrossRefPubMed
  126. Motzer R, Rini B, McDermott D, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019; 20(10): 1370–1385.
    CrossRef
  127. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018; 378(14): 1277–1290.
    CrossRefPubMed
  128. Rini B, Plimack E, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New Eng J Med. 2019; 380(12): 1116–1127.
    CrossRef
  129. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12): 1103–1115.
    CrossRefPubMed
  130. Choueiri TK, Powles T, Burotto M, et al. 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. Annals of Oncology. 2020; 31: S1159.
    CrossRef
  131. Choueiri T, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New Eng J Med. 2021; 384(9): 829–841.
    CrossRefPubMed
  132. Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New Eng J Med. 2021; 384(14): 1289–1300.
    CrossRefPubMed
  133. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010; 116(18): 4256–4265.
    CrossRefPubMed
  134. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013; 14(6): 552–562.
    CrossRefPubMed
  135. Choueiri TK, Escudier B, Powles T, et al. METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016; 17(7): 917–927.
    CrossRefPubMed
  136. Motzer RJ, Escudier B, George S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19): 1803–1813.
    CrossRefPubMed
  137. Cella D, Grünwald V, Nathan P, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol. 2016; 17(7): 994–1003.
    CrossRefPubMed
  138. Cella D, Escudier B, Tannir NM, et al. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. J Clin Oncol. 2018; 36(8): 757–764.
    CrossRefPubMed
  139. Wells JC, Stukalin I, Norton C, et al. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2017; 71(2): 204–209.
    CrossRefPubMed
  140. Naito S, Ichiyanagi O, Kato T, et al. Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma. Sci Rep. 2019; 9(1): 15451.
    CrossRefPubMed
  141. Vallet S, Pahernik S, Höfner T, et al. Efficacy of targeted treatment beyond third-line therapy in metastatic kidney cancer: retrospective analysis from a large-volume cancer center. Clin Genitourin Cancer. 2015; 13(3): e145–e152.
    CrossRefPubMed
  142. Ralla B, Erber B, Goranova I, et al. Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysis. World J Urol. 2016; 34(8): 1147–1154.
    CrossRefPubMed
  143. Yip SM, Wells C, Moreira R, et al. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer. 2018; 124(18): 3677–3683.
    CrossRefPubMed
  144. Santoni M, Heng DY, Bracarda S, et al. Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Cancers (Basel). 2019; 12(1).
    CrossRefPubMed
  145. Procopio G, Prisciandaro M, Iacovelli R, et al. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. Clin Genitourin Cancer. 2018; 16(4): e945–e951.
    CrossRefPubMed
  146. Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15(3): 286–296.
    CrossRefPubMed
  147. Escudier B, Sharma P, McDermott DF, et al. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. Eur Urol. 2017; 72(6): 962–971.
    CrossRefPubMed
  148. Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016; 17(3): 378–388.
    CrossRefPubMed
  149. Tannir NM, Jonasch E, Albiges L, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016; 69(5): 866–874.
    CrossRefPubMed
  150. Lee CH, Voss M, Carlo M, et al. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial. Journal of Clinical Oncology. 2021; 39(15_suppl): 4509–4509.
    CrossRef
  151. Lee CH, Voss M, Carlo M, et al. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial. Journal of Clinical Oncology. 2021; 39(15_suppl): 4509–4509.
    CrossRef
  152. Oudard S, Banu E, Vieillefond A, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. J Urol. 2007; 177(5): 1698–1702.
    CrossRefPubMed
  153. Shah AY, Karam JA, Malouf GG, et al. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017; 120(6): 782–792.
    CrossRefPubMed
  154. Iacovelli R, Modica D, Palazzo A, et al. Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. Can Urol Assoc J. 2015; 9(3-4): E172–E177.
    CrossRefPubMed
  155. Dason S, Allard C, Sheridan-Jonah A, et al. Management of renal collecting duct carcinoma: a systematic review and the McMaster experience. Curr Oncol. 2013; 20(3): e223–e232.
    CrossRefPubMed
  156. Beckermann KE, Sharma D, Chaturvedi S, et al. Renal Medullary Carcinoma: Establishing Standards in Practice. J Oncol Pract. 2017; 13(7): 414–421.
    CrossRefPubMed
  157. Derosa L, Silva CA, Dalban C, et al. 657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study. Annals of Oncology. 2021; 32: S681.
    CrossRef
  158. Elkrief A, Derosa L, Kroemer G, et al. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann Oncol. 2019; 30(10): 1572–1579.
    CrossRefPubMed
  159. Juusela H, Malmio K, Alfthan O, et al. Preoperative irradiation in the treatment of renal adenocarcinoma. Scand J Urol Nephrol. 1977; 11(3): 277–281.
    CrossRefPubMed
  160. Paly JJ, Hallemeier CL, Biggs PJ, et al. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2014; 88(3): 618–623.
    CrossRefPubMed
  161. Kjaer M, Iversen P, Hvidt V, et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol. 1987; 21(4): 285–289.
    CrossRefPubMed
  162. Ulutin HC, Aksu G, Fayda M, et al. The value of postoperative radiotherapy in renal cell carcinoma: a single-institution experience. Tumori. 2006; 92(3): 202–206.
    CrossRefPubMed
  163. Tunio MA, Hashmi A, Rafi M. Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials. Ann Oncol. 2010; 21(9): 1839–1845.
    CrossRefPubMed
  164. Chang JH, Cheung P, Erler D, et al. Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma in Non-surgical Candidates: Initial Clinical Experience. Clin Oncol (R Coll Radiol). 2016; 28(9): e109–e114.
    CrossRefPubMed
  165. Dabestani S, Marconi L, Hofmann F, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014; 15(12): e549–e561.
    CrossRefPubMed
  166. Kothari G, Foroudi F, Gill S, et al. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol. 2015; 54(2): 148–157.
    CrossRefPubMed
  167. Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017; 18(8): 1040–1048.
    CrossRefPubMed
  168. Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017; 18(8): 1049–1060.
    CrossRefPubMed
  169. Lee J, Hodgson D, Chow E, et al. A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer. 2005; 104(9): 1894–1900.
    CrossRefPubMed
  170. Siva S, Kothari G, Muacevic A, et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol. 2017; 14(9): 549–563.
    CrossRefPubMed
  171. Scoll BJ, Wong YN, Egleston BL, et al. Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol. 2009; 181(2): 506–511.
    CrossRefPubMed
  172. Capitanio U, Cloutier V, Zini L, et al. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJU Int. 2009; 103(11): 1496–1500.
    CrossRefPubMed
  173. Beisland C, Guðbrandsdottir G, Reisæter LAR, et al. A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use. World J Urol. 2016; 34(8): 1087–1099.
    CrossRefPubMed
  174. Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004; 22(16): 3316–3322.
    CrossRefPubMed
  175. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002; 20(23): 4559–4566.
    CrossRefPubMed
  176. Pettus JA, Jang TL, Thompson RH, et al. Effect of baseline glomerular filtration rate on survival in patients undergoing partial or radical nephrectomy for renal cortical tumors. Mayo Clin Proc. 2008; 83(10): 1101–1106.
    CrossRefPubMed
  177. Bruno JJ, Snyder ME, Motzer RJ, et al. Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. BJU Int. 2006; 97(5): 933–938.
    CrossRefPubMed
  178. Sandhu SS, Symes A, A'Hern R, et al. Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. BJU Int. 2005; 95(4): 522–525.
    CrossRefPubMed
  179. Bani-Hani AH, Leibovich BC, Lohse CM, et al. Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients. J Urol. 2005; 173(2): 391–394.
    CrossRefPubMed
  180. Patard JJ, Shvarts O, Lam JS, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol. 2004; 171(6 Pt 1): 2181–218.
    CrossRefPubMed
  181. Karakiewicz PI, Briganti A, Chun FKH, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007; 25(11): 1316–1322.
    CrossRefPubMed
  182. Lam JS, Shvarts O, Leppert JT, et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005; 174(2): 466–472.
    CrossRefPubMed

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl